| Literature DB >> 31405375 |
Cristian V Crisan1,2,3, Aroon T Chande2,3,4,5, Kenneth Williams1,2,3, Vishnu Raghuram1,2,3, Lavanya Rishishwar2,3,4,5, Gabi Steinbach2,4,6, Samit S Watve7, Peter Yunker2,4,6, I King Jordan2,3,4,5, Brian K Hammer8,9,10.
Abstract
BACKGROUND: Like many bacteria, Vibrio cholerae deploys a harpoon-like type VI secretion system (T6SS) to compete against other microbes in environmental and host settings. The T6SS punctures adjacent cells and delivers toxic effector proteins that are harmless to bacteria carrying cognate immunity factors. Only four effector/immunity pairs encoded on one large and three auxiliary gene clusters have been characterized from largely clonal, patient-derived strains of V. cholerae.Entities:
Keywords: Bacterial toxins; Type VI secretion clusters; Vibrio cholerae
Mesh:
Substances:
Year: 2019 PMID: 31405375 PMCID: PMC6691524 DOI: 10.1186/s13059-019-1765-5
Source DB: PubMed Journal: Genome Biol ISSN: 1474-7596 Impact factor: 13.583
Fig. 1Type VI secretion system of Vibrio cholerae. a Diagrammatic depiction of the T6SS apparatus extension and contraction in V. cholerae. The apparatus is composed of a membrane-spanning and a baseplate complex, an outer contractile sheath (VipA/B), and a needle complex (Hcp and VgrG). Effectors can interact directly with VgrG or PAAR proteins, may require chaperones for delivery on the apparatus, or be carried as cargo in the T6SS apparatus. b Aux clusters 1, 2, and 4 share a canonical hcp, vgrG, tap, effector, immunity gene organization in all strains where they are found
Fig. 2A wide diversity of T6SS effectors is found in sequenced clinical and environmental V. cholerae strains. The ANI matrix includes 25 strains from this study and 14 high-quality publicly available reference V. cholerae genomes from NCBI. ANI one-way and reciprocal best hit were used to determine protein identity between sequences. Strains that are grouped together share similar phenotypes and type VI secretion effector-immunity proteins. A “+” sign in front of the strain name in bold depicts the respective strain possesses the gene encoding the cholera toxin. The numbers above the boxes represent the Aux clusters found in those strains: L (large), 1, 2, 3, 4, 5
Fig. 3Aux 5 clusters have an atypical gene organization and encode predicted lipases. a The novel Aux 5 cluster sequences from the four distinct genomic loci were aligned. The atypical Aux cluster organization is observed in all four Aux 5 clusters. Numbers at the beginning of the clusters represent the genomic position on the BGT49 chromosome. b The structure of TleV1 was predicted using the Phyre2 webserver. The Pseudomonas aeruginosa Tle1 crystal structure is predicted with high confidence to be homologous to the Aux 5 putative effector. The color scheme depicts the alignment confidence of the Phyre2 model to the Tle1 crystal structure. The image was obtained using JSmol. c Aux 5-like clusters were identified in other V. cholerae strains and an Aeromonas strain and analyzed phylogenetically
Fig. 4TleV1 is toxic to both E. coli and V. cholerae cells. a Wild-type and periplasmic Tat-tagged tleV1 genes were expressed in E. coli cells under the control of the pBAD promoter. Cells carrying the effector were then spotted on glucose 0.2% or arabinose 0.2% plates (and antibiotic to maintain the plasmid). b The clinical wild-type C6706 V. cholerae strain was competed with C6706* (a C6706 strain that constitutively expresses QstR and the T6SS apparatus) with an integrated Aux 5a cluster (C6706*:Aux 5a) at its lacZ gene locus. A T6SS− C6706*:Aux 5a mutant and a C6706*:Aux 5a ΔtleV1 mutant were also competed against the WT C6706 target. A one-way ANOVA with post-hoc Tukey HSD test was performed, ****p < 0.0001. c Competitions between WT C6706 vs. C6706*:Aux 5a and WT C6706 vs. C6706*:Aux 5a ΔtleV1 were visualized using propidium iodide (staining red cells with a compromised membrane) as an indicator for cellular lysis. Black scale bars represent 40 μM
Fig. 5TliV1a acts as an immunity protein and neutralizes the toxic effects of TleV1. a E. coli cells expressing both Tat-tleV1 and either tliV1a or Tat-tliV1a were grown on glucose 0.2% and arabinose 0.2% (and respective antibiotics to maintain both plasmids). b Survival of target C6706 cells carrying a plasmid control, ptliV1a, or ptat-tliV1a after being competed with killer C6706*:Aux 5a. A one-way ANOVA with post-hoc Tukey HSD test was performed, ***p < 0.001, *p < 0.05